SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
CYTOCLONAL PHARMACEUTICS
________________________________________________________________________
(Name of Issuer)
Common Stock
________________________________________________________________________
(Title of Class of Securities)
23282G105
________________________________________________________________________
(CUSIP Number)
Paul F. Byrne c/o Janssen-Meyers Associates, L.P.
17 State Street,
NY, NY 10004 (212) 742-4200
________________________________________________________________________
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and
Communications)
11/2/95
_______________________________________________________________
_________(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the
acquisition which is the subject of this
Schedule 13D, and is filing this schedule because
of Rule 13d-1(b)(3) or (4), check the following box_____.
Check the following box if a fee is
being paid with the statement _____. (A fee is not required
only if the reporting person: (1) has a
previous statement on file reporting beneficial ownership
of more than five percent of the class of
securities described in Item1; and (2) has filed no
amendment subsequent thereto reporting beneficial
ownership of five percent of less of such class.)
(Sec Rule 13d-7.)
Note: Six copies of this statement, including
all exhibits, should be filed with the
Commission. See Rule 13d-1(a) for other parties
to whom copies are to be sent.
*The remainder of this cover page
shall be filled out for a reporting person's
initial filing on this
form with respect to the subject class of
securities, and for any subsequent amendment
containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this
cover page shall not be deemed to be
filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that
section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
1. Name of Reporting Person
Peter Janssen
_____________________________________________________
S.S. or I.R.S. Identification No. of Above Person
_____________________________________________________
2. Check the Appropriate Box if a Member of a Group
(See Instructions before filling out)
a.________ b____X__
3. SEC USE ONLY
_____________________________________________________
4. Source of Funds (See instructions before filling out).
AF
______________________________________________________
5. Check Box if Disclosure of Legal Proceedings is
Required Pursuant to Items
2(d) or 2(e).
_____________________________________________________________________________
6. Citizenship or Place of Organization
USA
____________________________________________________
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING
PERSON (Questions 7 - 10)
7. Sole Voting Power
____________________________________________________
8. Shared Voting Power
840,000 Common Stock
_____________________________________________________
9. Sole Dispositive Power
_____________________________________________________
10. Shared Dispositive Power
840,000 shares Common Stock
_____________________________________________________
11. Aggregate Amount Beneficially Owned
by Each Reporting Person
840,000 shares Common Stock
_____________________________________________________
12. Check Box if the Aggregate Amount in Row
(11) Excludes Certain Shares
(See instructions before filling out)
NA
_____________________________________________________
13. Percent of Class Represented by Amount in Row (11)
10.8%
______________________________________________________
14. Type of Reporting Person (See instructions before filling out)
IN
______________________________________________________
